You are here

Article Text

Article menu
Download PDFPDF
Commentary
Role of secondary cytoreduction in relapsed ovarian cancer

https://doi.org/10.1136/ijgc-2024-005876

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    PDF extract preview

    You do not have access to the full text of this article, the first page of the PDF of this article appears above.

    Footnotes

    • X @mcgouveia_, @marianascarant1

    • MCG and YRS contributed equally.

    • Contributors Study concept: MS. Drafting of the commentary: MCG, YRS, and AJR. Critical revision of the commentary: MS and GB.

    • Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

    • Competing interests MCG: Speaker fees: Novartis, Knight Therapeutics. GB: AstraZeneca, GSK and MSD. MS: Speaker fees and/or honoraria for consulting or advisory functions: MSD, AstraZeneca, Libbs, GSK, Zodiac, Roche, Orentt, MDHealth, Sanofi, Gilead, Amgen, Sophia genetics. YRS and AJR have no competing interests to declare.

    • Provenance and peer review Not commissioned; internally peer reviewed.